Immuno-co-culture killing model platform by InnoModels Biotechnology
- Categories:Company news
- Author:InnoModels
- Origin:InnoModels
- Time of issue:2024-08-21 15:51
- Views:
(Summary description)In the field of life sciences and pharmaceutical research and development, innovation is the key to driving technological advancement and disease treatment. InnoModels Biotechnology (Beijing), as a leader in this field, has provided strong support for cancer treatment and immunotherapy research through its innovative immunoco-culture killing model platform. In this article, we will introduce this platform in detail and discuss its important role in research and clinical applications.
Immuno-co-culture killing model platform by InnoModels Biotechnology
(Summary description)In the field of life sciences and pharmaceutical research and development, innovation is the key to driving technological advancement and disease treatment. InnoModels Biotechnology (Beijing), as a leader in this field, has provided strong support for cancer treatment and immunotherapy research through its innovative immunoco-culture killing model platform. In this article, we will introduce this platform in detail and discuss its important role in research and clinical applications.
- Categories:Company news
- Author:InnoModels
- Origin:InnoModels
- Time of issue:2024-08-21 15:51
- Views:
In the field of life sciences and pharmaceutical research and development, innovation is the key to driving technological advancement and disease treatment. InnoModels Biotechnology (Beijing), as a leader in this field, has provided strong support for cancer treatment and immunotherapy research through its innovative immunoco-culture killing model platform. In this article, we will introduce this platform in detail and discuss its important role in research and clinical applications.
Background and Establishment of the Platform
Ltd. was co-founded by scientists from Novo Nordisk China R&D Center, Sino-US Champion and the Institute of Immunology of Shanghai Jiao Tong University. Since its establishment, the company has been focusing on oncology and tumor immunopharmacodynamics CRO services, translational medicine research services and individualized medicine, and is committed to providing a new generation of experimental animal models close to the clinic. Its immune co-culture killing model platform is an important technological breakthrough in this direction.
Platform Features and Technical Advantages
1. Precise cell culture technology
Through advanced cell culture technology, the immune co-culture killing model constructs a more realistic three-dimensional tissue structure, simulating the complex interaction between immune cells and tumor cells in the body. This model not only improves the biological realism of experiments, but also enables researchers to more accurately predict the effects of therapeutic drugs in the body.
2. Introduction of multiple cell types
Unlike traditional immune models, this model is able to introduce multiple immune cell types at the same time, such as natural killer cells (NK cells) and T cells. The introduction of multiple cell types makes the simulated immune response process more complex and closer to the real situation, and the experimental results are more biologically meaningful.
3. Advanced Microscopy and Imaging Analysis
The platform uses advanced microscopy technology and imaging analysis to provide real-time observation at the cellular level. This visualization feature enables researchers to intuitively observe the killing process of immune cells and gain a deeper understanding of the mechanism of immunotherapy.
4. Exhaustive biomarker analysis
The model allows detailed analysis of biomarkers in the immune response, helping researchers to discover potential predictive indicators that provide an important basis for clinical research and the design of therapeutic regimens.
Application Areas and Impact
1. Cancer therapeutic research
The immune co-culture killing model has a wide range of applications in cancer therapy research. It can efficiently and accurately assess the immuno-killing effect of potential therapeutic drugs, optimize the engineering of immune cells, and improve their recognition and killing ability of tumor cells. In addition, based on a patient's immune profile, the platform can customize treatment plans and improve the individualization of treatment.
2. Drug Screening and Evaluation
The platform can be used for large-scale drug screening to assess the killing effect and toxicity level of drugs on cells, providing important data for safety assessment during drug development. This efficient screening mechanism helps to shorten the cycle of new drug development and reduce R&D costs.
3. Translational Medicine and Individualized Medicine
InnoModels' immune co-culture killing model platform also promotes the development of translational medicine and individualized medicine. By providing an experimental platform that is closer to the actual clinical situation, researchers are able to understand the disease mechanism and therapeutic effects more deeply, providing more accurate guidance for clinical diagnosis and treatment.
Conclusion
The launch of InnoModels' immune co-culture killing model platform marks an important leap in immunotherapy research. With its precise technology, wide range of applications and far-reaching impact, the platform provides a solid scientific foundation for research on cancer treatment and immunotherapy. In the future, with the continuous advancement of technology and in-depth expansion of applications, InnoModels Biotechnology will continue to play an important role in life science and pharmaceutical R&D, bringing more hope and possibilities to patients.
- Tel 15010000264
- E-mail limy@imodels.tech
- Tel 13810723384
- Top
InnoModels Biotechnology (Beijing) Co., Ltd.
TEL:15010000264 13810723384
Email:cndw@imodels.tec
Address:Building 14, Life Valley, Shuangying West Road, Changping District, Beijing
Chuangmo Biotechnology (Beijing) Co., Ltd. Beijing ICP 222*** 98-1 Website Construction: China Enterprise Power Beijing Second Branch Company